Evidence map›Paper›PMID 31809634›Full record

ArticleGut microbes2020

Changes in gut microbial metagenomic pathways associated with clinical outcomes after the elimination of malabsorbed sugars in an IBS cohort.

A Mack, J S Bobardt, A Haß, K B Nichols, R M Schmid, C K Stein-Thoeringer

Open access · goldAbstract read
In one paragraph

Article in Gut microbes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 19 citations in OpenAlex.

  1. Trial
  2. Article
  3. GLUT5: structure, functions, diseases and potential applications.Acta biochimica et biophysica Sinica · 2023
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

A MackKlinik und Poliklinik fuer Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich , Munich, Germany.
J S BobardtKlinik und Poliklinik fuer Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich , Munich, Germany.
A HaßKlinik und Poliklinik fuer Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich , Munich, Germany.
K B NicholsSloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSKCC) , New York, USA.
R M SchmidKlinik und Poliklinik fuer Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich , Munich, Germany.
C K Stein-ThoeringerKlinik und Poliklinik fuer Innere Medizin II, Klinikum rechts der Isar, Technical University of Munich , Munich, Germany.
Klinikum rechts der Isar · DEMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Specific diets to manage sugar malabsorption are reported to reduce clinical symptoms of irritable bowel syndrome (IBS). However, the effects of diets for malabsorbed sugars on gut microbiota signatures have not been studied, and associations with clinical outcomes in IBS have not been characterized. 22 IBS patients positively tested for either lactose-, fructose-, sorbitol- or combined malabsorptions were subjected to 2-weeks sugar elimination and subsequent 4-weeks re-introduction. 7 IBS patients tested negative for sugar malabsorption were used as controls. Nutrition and clinical symptoms were recorded throughout the study. Fecal samples were serially collected for 16S rRNA amplicon and shotgun-metagenome sequencing. Dietary intervention supervised by nutrition counseling reduced IBS symptoms during the elimination and tolerance phases. Varying clinical response rates were observed between subjects, and used to dichotomize our cohort into visual analogue scale (VAS) responders and non-responders. Alpha -and beta-diversity analyzes revealed only minor differences regarding 16S rRNA-based fecal microbiota compositions between responder and non-responder patients during baseline or tolerance phase. In shotgun-metagenome analyzes, however, we analyzed microbial metabolic pathways and found significant differences in pathways encoding starch degradation and complex amino acid biosynthesis at baseline between IBS controls and malabsorbers, and notably, between diet responder and non-responders.

Indexed as

Gastrointestinal MicrobiomeAdultAgedCohort StudiesDNA, BacterialFecesFemaleHumansIrritable Bowel SyndromeMalabsorption SyndromesMaleMetabolic Networks and PathwaysMetagenomeMetagenomicsMiddle AgedRNA, Ribosomal, 16SDNA, BacterialRNA, Ribosomal, 16SSugarsCarbohydrate malabsorptiondietirritable bowel syndromemicrobiome

Identifiers

PMID31809634
PMCPMC7524390
OpenAlexW2992474544

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.